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(57) ABSTRACT 
Described herein are particular embodiments relating to a 
microfluidic device that may be utilized for cell sensing, 
counting, and/or sorting. Particular aspects relate to a micro-
fabricated device that is capable of differentiating single cell 
types from dense cell populations. One particular embodi-
ment relates a device and methods of using the same for 
sensing, counting, and/or sorting leukocytes from whole, 
undiluted blood samples. 
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crate more waste than the systems developed using microde-
vices. Furthermore, for analysis of certain cell types, such as 
leukocytes, accuracy and speed of counting, differentiation, 
and/or sorting is important for determining disease state and 
5 treatment. 
MICROFLUIDIC DEVICE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This present application is a divisional of U.S. Ser. No. 
12/062,808, filed Apr. 4, 2008, currently pending, which 
claims the benefit of priority of U.S. provisional application 
No. 60/922,296, filed Apr. 6, 2007, the contents of each which 
are herein incorporated by reference in their entirety. 
STATEMENT OF GOVERNMENT INTEREST 
This work was supported in part by the National Space 
Biomedical Research Institute through NASA, grant number 
NCC 9-58-317. The United States government has certain 
rights in this invention. 
FIELD OF THE INVENTION 
The present disclosure relates to fabricated microfluidic 
devices that can be utilized as cell sensors and/or actuators. In 
certain embodiments, the microfluidic device may be used for 
labeling, sensing differentiating, and/or sorting targets, par-
ticularly cell populations. 
BACKGROUND OF THE INVENTION 
Standard cell sensors or actuators are generally based on 
flow cytometry and employ one or a combination of electrical 
impedance sensing, light scattering measurement, and chemi-
cal or immunostaining followed by optical sensing. 
For differentiation of blood cells by electrical impedance 
sensing, red blood cells are removed by lysing in order to 
reduce the blood volume. Lysing is generally done through 
the use of saponin or surfactants. During the lysing process, 
the leukocyte cell volume changes depending on cell type, 
due to the leakage of cytoplasm contents and cell nucleus 
shrinkage in varying amounts. Fujimoto, Sysmex J. Int. 9 
(1999). Thus, normally 2-part (lymphocytes versus granulo-
cytes) or even 3-part (lymphocytes, neutrophils, and other 
leukocytes) differential can be achieved by simple electrical 
impedance measurement of particle volume. Hughes-Jones, 
et al., J. Clin. Patol. 27; 623-625 (1974); Oberjat, et al., J. Lab. 
Clin. Med. 76; 518 (1970); Vandilla, et al., Proc. Soc. Exp. 
Biol. Med. 125; 367 (1967); Maeda, et al., Clin. Pathol. 27; 
1117-1200 (1979); Maeda, et al., Clin. Pathol. 9; 555-558 
(1982). Combining direct current and alternating current 
impedance, special acidic hemolysis in basophile channel 
and alkali hemolysis in eosinophil channel, a 5-part leukocyte 
differential can be achieved. Tatsumi, et al., Sysmex J. Int. 9; 
9-20 (1999). 
Alternative optical methods are based on light scattering 
and fluorescence staining of organelles, granules, and nuclei. 
Generally, low-angle scattered light contains information on 
cell size and high-angle scattered light can be used to probe 
internal composition of the cell. To achieve 5-part differen-
tial, certain leukocyte populations, such as eosinophils, 
require special stain to change its scattering characteristics 
from other granulocytes, and basophils typically need to be 
counted separately following the differential lysis of other 
leukocytes. McKenzie, Clinical Laboratory Hematology, 
Prentice Hall, 2004; Fujimoto, Sysmex J. Int. 9 (1999). 
In general, conventional automated cell analyzers are 
bulky, expensive, and mechanically complex, which restricts 
their locations to hospitals or central laboratories. Conven-
tional cell analyzers require larger sample volumes and gen- 
BRIEF DESCRIPTION OF THE SEVERAL 
VIEWS OF THE DRAWING(S) 
10 	 FIG. 1A shows the molecular structure of acridine orange. 
FIG. 1B shows leukocyte staining results with acridine 
orange. 
FIG. 2 shows the top view of one embodiment of a novel 
15 fabricated microfluidic apparatus. 
FIG. 3 shows one embodiment of the optical system setup. 
FIG. 4A shows erythrocyte concentration in whole blood. 
FIG. 4B shows leukocyte staining in whole blood with 
acridine orange at a concentration of 100 ng/mL. 
20 	 FIG. 4C shows leukocyte staining in whole blood with 
acridine orange at a concentration of 1 µg/mL. 
FIG. 4D shows leukocyte staining in whole blood with 
acridine orange at a concentration of 10 µg/mL. 
FIG. 4E shows leukocyte staining in whole blood with 
25 acridine orange at a concentration of 100 µg/mL. 
FIG. 4F shows leukocyte staining in whole blood with 
acridine orange at a concentration of 1 mg/mL. 
FIG. 5 shows fluorescent signal bleaching from a single 
leukocyte in one embodiment. 
30 FIG. 6A shows an image of background and a 5 M bead 
with focused laser illumination flow taken by CCD camera 
with long pass emission filter, according to one embodiment. 
FIG. 6B shows an image of background and a 5 µm bead 
35 with laser illumination flow taken by CCD camera with long 
pass emission filter, according to one embodiment. 
FIG. 6C shows an image of background and a 5 µm bead 
with diffused laser illumination flow taken by CCD camera 
with long pass emission filter, according to one embodiment. 
40 FIG. 6D shows an image of background and the trace of a 
5 µm bead with diffused laser illumination flow taken by CCD 
camera with long pass emission filter, according to one 
embodiment. 
FIG. 7 shows a graph of detection of 5 µm fluorescent beads 
45 detection with photodiode detector with long pass emission 
filter. 
FIG. 8A shows background image of focused laser beam 
from video taken by CCD camera with long pass emission 
filter, according to one embodiment. 
50 	 FIG. 8B shows a signal from a leukocyte from diluted 
whole blood testing from video taken by CCD camera with 
long pass emission filter, according to one embodiment. 
FIG. 9 shows the time trace of amplified photodiode signal 
of acridine orange stained undiluted whole blood with green 
55 
emission filter centered at 525 mu, and peaks labeled, accord-
ing to one embodiment. 
FIG. 10 shows a histogram of signal intensity from photo-
diode detector with green emission filter centered at 525 mu. 
60 
	
FIG. 11 shows a histogram of signal intensity from photo- 
diode detector with red emission filter centered at 650 mu. 
FIG. 12A shows an illustration of a handheld detection box 
instrument according to one embodiment. 
FIG. 12B shows an assembled detection box instrument 
65 according to one embodiment. 
FIG. 13A shows the top view of an apparatus according to 
one particular embodiment. 
US 9,029,158 B2 
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FIG. 13B shows the top view of an apparatus according to 
one particular embodiment. 
SUMMARY OF THE INVENTION 
Certain embodiments disclosed herein include a microflu-
idic apparatus comprising a substrate having a first channel 
having a definedphysical feature, wherein said first channel is 
in fluid communication with at least one inlet for receiving a 
fluid, wherein said first channel leads to a restrictive access, io 
and wherein said first channel is in fluid communication with 
a second channel having a defined physical feature, wherein 
said second channel is in fluid communication with at least 
one fluid flow outlet; and a fluid biological sample. In certain 
embodiments, said defined physical feature is a depression or 15 
protrusion. In particular embodiments, said fluid biological 
sample comprises blood. In certain embodiments, the microf-
luidic apparatus further comprises a detection zone, and/or a 
filter array, each in fluid communication with said channel 
and said fluid flow outlet. 20 
A microfluidic apparatus comprising a substrate having at 
least one first channel having a defined physical feature; at 
least one first inlet formed in said first channel for receiving a 
first fluid; wherein said first channel is in fluid communica-
tion with a bifurcated channel, wherein said bifurcated chan- 25 
nel is in fluid communication with a third channel detection 
zone; at least one second inlet for receiving a second fluid, 
wherein said second inlet is in fluid communication with a 
branched channel; a filter structure in fluid communication 
with a reservoir, wherein said reservoir is in fluid communi- 30 
cation with said third channel detection zone; at least one fluid 
flow outlet formed in said third channel; and a fluid sample; 
wherein the ratio of the cross-sectional area of said second 
channel compared to the cross-sectional area of said first 
channel is 1:10. In certain embodiments, the defined physical 35 
feature is a depression or a protrusion. 
In certain embodiments, said filter structure comprises a 
filter array, said first fluid comprises sheath fluid and said 
second fluid comprises blood. 
Certain embodiments disclosed herein relate to a detection 40 
system comprising microfluidic apparatus and further com-
prising a light source; a lens assembly; a filter assembly; and 
an image capture device. In some embodiments, the detection 
system further comprises at least one display unit or at least 
one recording unit. In certain particular embodiments, said 45 
excitation source comprises a laser, particularly an argon 
laser. In particular embodiments, said filter assembly com-
prises an excitation filter, and at least one emission filter. In 
certain embodiments, said filter assembly further comprises 
at least one aperture and at least one neutral density filter. In 50 
particular embodiments, said filter assembly further com-
prises at least one glass polarizer. 
In certain embodiments, the lens assembly of the detection 
system comprises at least one condenser lens, at least one 
objective lens, and at least one beamsplitter. In particular 55 
embodiments, said image capture device comprises at least 
one CCD camera, CMOS device, photodiode, or photomul-
tiplier tube. In certain embodiments, said filter assembly 
comprises at least two emission filters and said image capture 
device comprises at least one photomultiplier tube. In certain 60 
embodiments, said display unit comprises a computer and 
said recording unit comprises an oscilloscope. In particular 
embodiments, said excitation source comprises an argon 
laser; said lens assembly comprises a condenser lens, an 
objective lens, and a beamsplitter; said filter assembly com- 65 
prises an excitation filter, a pinhole aperture and a neutral 
density filter, and at least one emission filter; said image  
4 
capture device comprises a CCD camera and a photodiode, 
and said display unit comprises a personal computer, and 
further comprising an amplifier. 
In particular embodiments, said excitation source of the 
detection system comprises an argon laser; said lens assem-
bly comprises a condenser lens, an objective lens, and a 
beamsplitter, said filter assembly comprises an excitation fil-
ter, at least one emission filter; said image capture device 
comprises a photomultiplier tube, and said display unit com-
prises a personal computer. 
Other embodiments disclosed herein relate to a method for 
identifying a target comprising providing a fluid sample to at 
least one microfiuldic apparatus, wherein said fluid sample 
contains at least one dye; providing an excitation source to 
induce at least one fluorescent signal in a target; detecting the 
fluorescent signal using as sensor in the apparatus; and iden-
tifying the target based in part on the analysis of the fluores-
cent signal. In certain embodiments, said target is selected 
from the group consisting of: cells, organelles, nuclei, gran-
ules, DNA, and RNA. In other embodiments, said target 
comprises a cell selected from the group consisting of a 
monocyte, a granulocyte, a macrophage, a neutrophil, an 
eosinophil, abasophil, or other leukocyte. In specific embodi-
ments, said target comprises a leukocyte and said dye com-
prises acridine orange. Particular embodiments of the method 
further comprising counting or sorting the target in the sample 
by analysis of the fluorescent signal. In certain embodiments, 
said fluid sample comprises blood. 
DETAILED DESCRIPTION OF THE INVENTION 
The present disclosure relates to fabricated microfluidic 
devices that can be utilized as cell sensors and/or actuators. In 
certain embodiments, the microfluidic device may be used for 
labeling, sensing, differentiating, and/or sorting cell popula-
tions. 
Microfluidic cell sensors and actuators can provide cell 
sensing and counting for a more accurate outcome and a 
lower cost. Particle counting (including bead, erythrocyte, 
and cultured cell) has been demonstrated, for example, by 
electrical impedance sensing, light scattering detection, and 
fluorescent sensing. Gawad, et al. Lab Chip 1; 76 (2001); Lee, 
et al. Proceedings of the 18 th IEEE International Conference 
on Micro Electro Mechanical Systems (MEMS) 678-681 
(2005); Satake et al. Sens. Actuators B: Chem. 83; 77 (2002); 
Morgan, et al. Curr. Appl. Phys. 6, 367-370 (2006); Lee et al., 
J. Micromech. Microeng. 15; 447-454 (2005); Altendorf, et 
al. Proceedings of the International Conference on Solid 
State Sensors and Actuators (Transducers '97) v.1, p. 531, 
Chicago, Ill. (1997); Holmes et al., Biosens. Bioelectron. 21; 
1621-1630 (2006); Yang et al., Meas. Sci. Technol. 17; 2001-
2009 (2006); Simonnet et al., Anal. Chem. 78; 5653-5663 
(2006); Niehren, et al., Anal. Chem. 67; 2666-2671 (1995). 
In the area of optical sensing, microfabrication has allowed 
development of microdevices to replace glass capillary-based 
flow chambers, and to integrate compact optics and provide 
on-chip sample transport. 
Cell sensing and counting, particularly of leukocytes, is 
cumbersome due in part to the cell population numbers. For 
leukocyte differential in microdevices based on optical sens-
ing, a V-groove microchannel was fabricated by anisotropic 
wet etching of a silicon substrate and 3 -part leukocyte differ-
ential was demonstrated for diluted blood without sheath flow 
by two-parameter light scattering. Altendorf, Proceedings of 
the Int'l Conference on Solid State Sensors and Actuators, v. 
1, p. 531 (1997). 
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However, until the instant embodied disclosure, it was 	 phils, and basophils) has been demonstrated with hypotonic 
	
necessary to dilute cell samples for cell sensors and actuators 	 dilution and fresh Acridine orange-stained leukocyte 
	
for many reasons. One reason dilution has been necessary is 	 samples. Adams and Kamentsky, Acta Cytol. 15, 289 (1971); 
	
in order to prevent the coincidence effect in which multiple 	 Adams and Kamentsky, Acta Cytol. 18, 389-391 (1974); 
cells appear in the detection zone simultaneously. In human 5 Steinkam et al., Acta Cytol, 17, 113-17 (1973). 
	
blood, the ratio of erythrocytes, or red blood cells, to leuko- 	 Other dyes can be utilized with certain embodiments 
	
cytes is on the order of about a thousand to one, a dilution 	 described in the instant disclosure, such as ethidium bromide, 
	
factor of from about one hundred to several tens of thousands 	 three-dye combinations (ethidium bromide, brilliant sulfafla- 
	
is typically required to avoid erythrocyte interference for 	 vine, and stilbene disulfonic acid derivative); oxazine dyes, 
electrical impedance or light scattering detection. Further-  io basic orange 21, and a polymethine dye. Shapiro, et al., His- 
	
more, for counting leukocytes in samples where leukocytes 	 tochem. Cytochem. 24, 396-411 (1976); Shapiro, et al., J. 
	
are specifically fluorescently labeled, a dilution of at least ten 	 Histochem. Cytochem. 25, 836-844 (1977); U.S. Pat. No. 
	
times is usually required. Sheenan and Storey, J. Pathol. 	 4,376,820; U.S. Pat. No. 4,882,284; Tibbe, et al., Nat. Bio- 
	
Bacteriol. 59; 336 (1947); Kass, J. Clin. Pathol. 76; 810-12 	 technol 17,1210-1213 (1999); U.S. Pat. No. 4,400,370; Kass, 
(1981); Weigl et al., Biomed Microdeu 3; 267-274 (2001). 15 J. Histochem. Cytochem, 36, 711-715 (1988). 
	
Dilution is also often required in order to avoid clogging 	 Apparatus 
	
sample chambers, and also in order to remove erythrocytes 	 One embodiment of the instant disclosure relates to a 
	
that are lysed prior to running the sample, particularly for 	 device or apparatus for cell counting and/or differentiating. In 
	
electrical impedance or light scattering detection. Some of 	 particular embodiments, the device or apparatus comprises a 
these protocols also require an additional fixation buffer. 	 20 substrate formed from a material, such as silicon, glass, plas- 
Dyes 	 tic, metal, or other material. One particular embodiment of 
	
In the present disclosure, a dye, such as Acridine orange 	 the instant disclosure was fabricated using soft lithography. 
	
(3,6-dimethylamineoacridine, FIG. 1), can be used to differ- 	 Quake, Science 290, 1536-40 (2000). Other photolitho- 
	
entiate a target, such as cells, organelles, granules, nuclei, 	 graphic or etching techniques could also be used, according to 
molecules (including double or single stranded nucleic acids, 25 specific embodiments. 
	
such as DNA, or RNA, chromosomes, and also including 	 One embodiment of the device was microfabricated using 
	
synthetic forms). In one particular embodiment, leukocytes 	 two parts of PDMS (polydimethylsiloxane) (Sylgard 184, 
	
may be detected, counted, or sorted without need for lysing 	 Dow Corning, Mich., USA) mixed vigorously in 10:1 ratio. 
	
erythrocytes or fixing the cell sample. Certain dyes, such as 	 After degassing in vacuum for about 30 minutes, the mixture 
Acridine orange, are also desirable due to the fast diffusion 30 was poured onto DRIE-etched silicon mold, that had been 
	
into cells, easy commercial availability, and excitation and 	 pretreated with HMDS (hexamethyldisilazane) for easy sepa- 
	
emission wavelength compatibility with common light 	 ration after baking. The molds were baked at 80° C. for 30 
	
sources (i.e. argon laser and other broad spectrum light 	 minutes. The hardened PDMS was separated from the silicon 
	
sources in visible range) and optical filters. Kosenow, Acta 	 mold, and PDMS sheet was cut into pieces and fluidic access 
Haematol. 7, 217 (1952); Schiffer, Blood, 19, 200 (1962); 35 holes were punctured on each piece with a Luer stub adapter 
	
Jackson, Blood, 17, 643 (196 1); Hallermann et al., PerhDeut- 	 (Becton Dickinson, N7, USA). Each PDMS piece was care- 
sch Gies Inn Med. 70, 217 (1964). 	 fully placed on a cleaned glass slide and baked overnight at 
	
Acridine orange is a pH-sensitive fluorescent cationic dye 	 80° C. In some cases, oxygen plasma treatment (300 m Torr, 
	
that binds to double-stranded DNA by electrostatic attraction 	 25 W, 30 s) was used for PDMS and glass slides in order to 
and intercalation of the Acridine orange between base pairs. 40 improve adhesion between them, particularly with devices 
	
Upon binding, the excitation maximum becomes 502 nm and 	 that were intended to be reused. Bhattacharya et al., J. Micro- 
	
the emission maximum becomes 525 nm (green). Acridine 	 electromechan. Syst. 14, 590-97 (2005). 
	
orange also binds to RNA and single-stranded DNA, with a 	 In one particular embodiment, the channel structure was 
	
shifted excitation maximum of 460 nm and an emission maxi- 	 molded on a 1 cmxI cm PDMS block, with the thickness of 
mum of 650 nm (red). Adams and Kamentsky, Acta Cytol. 15, 45 the PDMS block at less than 3 mm. In one particular embodi- 
	
289 (1971); Adams and Kamentsky Acta Cytol. 18, 389-91 	 ment the channel depth was 16 µm in order to accommodate 
	
(1974); Steinkam et al., Acta Cytol. 17,113-17 (1973). Acri- 	 large leukocyte sizes. 
	
dine orange is also desirable in that it is hydrophobic in 	 One exemplary embodiment of the device is shown in FIG. 
	
neutral pH, and can easily diffuse through the cell membrane 	 2. For this particular embodiment, a first fluid flow inlet 200 
and cell nuclear membrane to bind to RNA and DNA. In 5o allows for deposition of, for example sheath flow fluid, and is 
	
living cells, Acridine orange is protonated in the acidic envi- 	 in fluid communication with a bifurcated channel with a first 
	
ronment of lysosomes, which makes it cationic, and prevents 	 channel arm 260 and a second channel arm 270 that both 
	
the dye from leaking out of lysosome membranes. Moriyama 	 converge at a junction of a reservoir 290 and the detection 
	
et al., J. Biochem. 92; 1333-36 (1982). WhenAcridine orange 	 zone 240. In this particular embodiment, the apparatus further 
is used for leukocyte analysis, the cell nucleus is stained green 55 comprises a second fluid flow inlet 210 that allows for depo- 
	
with slightly mixed red, a result of double-stranded DNA and 	 sition of, for example, a sample fluid, such as blood, that is in 
	
single-stranded RNA while the cell cytoplasm is stained red 
	
fluid communication with a filter array structure 230, byway 
	
due to the RNA and lysosomes. Thus, leukocyte counting can 	 of a branched sample flow zone channel 220 and a fluid flow 
	
be achieved easily by using the strong signal from the green 	 outlet 250. In this particular exemplary embodiment, 2 -D 
fluorescent channel. Leukocyte differentiation can be 6o hydrodynamic focusing was adopted to control the particle 
	
achieved by analyzing the signal from the red fluorescence 	 position of the cell sample in the detection zone 240. Accord- 
channel. 	 ing to the embodiment shown in FIG. 2, the ratio of cross- 
	
For fresh-stained leukocytes, a 3 -part differential (lympho- 	 sectional area of sheath flow to core sample flow was 10:1, 
	
cytes, monocytes, and granulocytes) can be achieved by 	 and the channel width of the detection zone 240 was 50 µm, 
studying the red fluorescent signal of an Acridine orange 65 with the width of the focused sample flow preferably 5 µm or 
	
stained diluted blood sample, whereas a 5 -part differential 
	
less. In particular embodiments, the channels comprise a 
	
leukocytes (lymphocytes, monocytes, neutrophils, eosino- 	 physical feature, such as a depression or a protrusion. 
US 9,029,158 B2 
7 
One other exemplary embodiment of the device is shown in 
FIG. 13A. For this particular embodiment, the fluid flow inlet 
1340 allows for deposition of a sample fluid, such as a bio-
logical sample, or other fluid sample containing a target. In 
one particular embodiment, the biological sample includes a 5 
cell sample, such as blood. In this exemplary embodiment, 
the fluid inlet is in fluid communication with a first channel 
1330 which contains a restrictive access 1320 that is juxta-
posed to a second channel 1310 which comprises the detec-
tion zone which is also in fluid communication with the fluid io 
flow outlet 1300. In certain embodiments, the height of the 
first and/or second channels is approximately 5 µm, approxi-
mately 8 µm, approximately 10 µm, approximately 12 µm, 
approximately 15 µm, approximately 20 µm, approximately 
25 µm, approximately 30 µm, approximately 35 µm, approxi- 15 
mately 40 µm, or any value therebetween. In certain embodi-
ments the width of the second channel is approximately 5 µm, 
10 µm, approximately 15 µm, approximately 20 µm, approxi-
mately 25 µm, approximately 30 µm, approximately 35 µm, 
approximately 40 µm, approximately 45 µm, approximately 20 
50 µm, or any value therebetween. In the exemplary embodi-
ment shown in FIG. 13A, the second channel width was 
approximately 20 µm in size. 
One other exemplary embodiment of the device is shown in 
FIG. 13B. For this particular embodiment, the fluid flow inlet 25 
1440 allows for deposition of a sample fluid, such as a bio-
logical sample, or other fluid sample containing a target. In 
one particular embodiment, the biological sample includes a 
cell sample, such as blood. In this exemplary embodiment, 
the fluid inlet is in fluid communication with a first channel 30 
1430 which contains a restrictive access 1420 that is juxta-
posed to a second channel 1410 which comprises the detec-
tion zone which is also in fluid communication with the fluid 
flow outlet 1400. In certain embodiments, the height of the 
first and/or second channels is approximately 5 µm, approxi- 35 
mately 8 µm, approximately 10 µm, approximately 12 µm, 
approximately 15 µm, approximately 20 µm, approximately 
25 µm, approximately 30 µm, approximately 35 µm, approxi-
mately 40 µm, or any value therebetween. In certain embodi-
ments, the width of the second channel is approximately 5 40 
µm, 10 µm, approximately 15 µm, approximately 20 µm, 
approximately 25 µm, approximately 30 µm, approximately 
35 µm, approximately 40 µm, approximately 45 µm, approxi-
mately 50 µm, or any value therebetween. In the exemplary 
embodiment shown in FIG. 1313, the second channel width 45 
was approximately 30 µm in size. 
Certain embodiments of the device use a focused laser 
source for illumination, since cell focusing in the detection 
zone 240 is highly desirable. However, other embodiments 
included in the present disclosure use a more uniform dif- 50 
fused light source and a slit aperture. Such embodiments 
utilize straight channel geometry without cell focusing. In 
one embodiment, the channel length of the detection zone 240 
is 1000 µm. A filter structure 230 upstream of the sample flow 
zone 220 may also be included in certain embodiments, 55 
which filtered out contaminants, including erythryocyte rou-
leaux, and other large particle aggregates to prevent clogging 
in the detection zone 240. In certain embodiments, the size of 
the rectangular pillar structure components of the filter struc-
ture 230 was 200 µmx40 µm. The spacing between the pillars 60 
in each of the three rows was 40 µm, 30 µm, and 20 µm 
respectively, which allows for even the largest leukocytes to 
pass through the filter region 230. 
System 
The optical system was setup on an optical bench as shown 65 
in FIG. 3 (transmitted laser-induced fluorescent detection 
system or LIF). In one particular embodiment, the system  
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setup comprises an excitation or laser source 300, a lens 
assembly 340, the microfluidic apparatus 350, an optional 
additional lens assembly 360, a filter assembly 320, 330, and 
an image capture device 390, 305. In certain embodiments, 
one or more emission filters comprise the filter assemblies 
320, 330. In certain embodiments, the image capture device 
395 comprises a charge coupled device (CCD) camera, a 
complementary metal-oxide-semiconductor (CMOS) device, 
or a photomultiplier tube (PMT) device. In particular embodi-
ments, the image capture device 395 may be coupled to com-
municate with a display unit or computing device 396, such as 
a personal computer. One of skill in the art would recognize 
that multiple and various computer software programs are 
available that allow for integration, compilation, analysis, 
reconfiguration, and other manipulation of data received from 
the system, particularly by way of the computing device 396. 
In one particular exemplary embodiment, an argon laser 
(National Laser NLC2I OBL, 488 nm, and 15-30 mW adjust-
able, Salt Lake City, Utah, USA) is used as the excitation 
source. An aperture 310 of 50 µm diameter is put in front of 
the laser output to facilitate, the alignment process and lower 
the illumination intensity. In certain embodiments, an 
optional laser-line bandpass filter (bandwith equal to about 
1.9 mn with a central wavelength of 488 mu) is used to further 
purify the laser source. In certain other embodiments, an 
optional neutral density filter (NDF) is used to attenuate laser 
excitation. Alternatively, the pinhole and NDF are replaced 
by two linear glass polarizers (Edmond Optics TECH SPEC, 
Barrington, N.J., USA) so that the illumination level on the 
device can be easily adjusted. 
In one particular embodiment, a long-working-distance 
microscope objective (USMCO M Plan Apo, 10x, 0.28 NA, 
Dayton, Nev., USA) is used as a condenser lens 340. Another 
long-working-distance microscope objective (Bausch & 
Lomb, 50x, 0.45 NA, Rochester, N.Y., USA) is used as an 
objective lens 380. In the same embodiment, three emission 
filters 320 are used in one particular test: 488 nm long pass 
filter (Chroma H1500 LP, transition width<4.9 mu, edge 
steepness=2.5 mu, Rockingham, Vt., USA), a greenbandpass 
filter with central wavelength 525 mn and a bandwidth 50 mn 
(Chrome D52550 m), and a red bandpass filter with central 
wavelength 650 nm and bandwidth 50 nm (Chrome D650 
50 m). A broadband non-polarizing hybrid cube beamsplitter 
370 (Newport 05BC17MB.1, 400-700 mu, R/T=45%/45%, 
Irvine, Calif., USA) is used to direct light to the photodiode 
detector 380 and CCD camera simultaneously. 
The signal is electrically amplified and detected either with 
a silicon photodiode receiver module 390 (Electro-Optical 
Systems, UVS-025-H, Phoenixville, Pa., USA) or a photon 
multiplier tube (PMT, Hamamatsu H5784-20, Japan). The 
voltage signal is sent to a deep memory oscilloscope (HP 
54645A, Palo Alto, Calif., USA). When the buffer in the 
oscilloscope is full, the data can be loaded to a computer and 
analyzed with a Matlab peak-detection program. Video may 
be taken with an analog CCD camera (Hitachi KP-D20B, 
Japan) at 30 frames per second and then converted to digital 
format and stored in a computer 396. Other imaging capture 
devices 395, such as CMOS, PMT, or still other devices may 
also be used with particular embodiments described herein. In 
certain exemplary test runs, the system set up utilizing a 
photodiode detector and PMT are more sensitive than the 
CCD camera and have a faster time response. During one 
exemplary test run, the optical system was first roughly 
aligned on a dummy device with the aid of images from CCD 
camera. A 10 µm diameter illumination spot on the detection 
zone is easily achieved with proper alignment. 
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As shown in FIG. 12A and FIG. 12B, the instant apparatus 
may be incorporated into a hand-held unit comprising a laser 
source such as a laser emitting diode or LED 120), at least one 
lens 190, at least one filter assembly with optional beamsplit-
ter 195, a microfluidic apparatus as described herein on a 
microchip or other substrate 185, an input/output port 130, at 
least one image capture device 100, 110, which may be a 
photomultiplier tube. In certain embodiments, the hand-held 
unit may be assembled and enclosed by an outer casing or 
casings 150, 180, and rivets or bolts 140, 160. 
Cell Detection 
One aspect of the instant disclosure relates to methods of 
counting and/or differentiating cells, particularly leukocytes, 
from undiluted cell samples, such as human or other animal 
blood, by utilizing microfabricated devices. In one exemplary 
embodiment, cell detection was conducted utilizing Acridine 
orange and fresh whole human blood. 
In one exemplary embodiment, fresh human blood was 
obtained from healthy donors and used within 3 days of 
collection. EDTA was added to the blood samples in order to 
prevent coagulation. For Acridine orange staining, the stock 
solution was added to obtain a final dye concentration of 10 
µg/mL in Ficoll-Paque Plus. Ficoll-Paque Plus was also used 
as the sheath flow solution. Fluorescent polystyrene beads (5 
µm green fluorescent beads) were purchased from Duke Sci-
entific Corporations, Fremont, Calif., USA. Cell nucleus 
stain Acridine orange was obtained from Molecular Probes, 
Eugene, Oreg., USA, and dissolved in water to achieve a 10 
mg/mL stock solution. Blood diluent Ficoll-Paque Plus was 
purchased from Amersham Biosciences, Sweden. Phosphate 
buffered saline (10xPBS) was obtained fromAmbion (9625), 
Austin, Tex., USA. 
Staining results were observed under a fluorescent micro-
scope (Nikon E800, Japan) with a triple and filter block 
DAPI-FITC-TRITC, which has excitation filter wavelengths 
of 385-400 mu, 475-490 mu, and 545-565 mu, and emission 
filter wavelengths of 450-465 mu, 505-535 nm and 580-620 
mu. Images were taken with a cooled CCD camera (RT-KE 
color 3-shot, Diagnostic Instruments, Sterling Heights, 
Mich., USA). Rough count of leukocytes was made with a 
hemactyometer (Hausser Scientific, Horsham, Pa., USA). 
When necessary, blood or fluorescent beads were diluted with 
Ficoll-Paque Plus (specific gravity 1.077 g/mL) to match the 
specific gravity of the solvent to leukocytes. All fluids were 
pumpedinto the devices using syringepumps (HarvardAppa-
ratus Pico Plus, Holliston, Mass., USA). 
In this particular embodiment, an analog CCD camera was 
used for video recording at a matched camera frame rate of 3 
nL/min sample flow rate and 30 nL/min sheath flow rate. For 
photodiode detection, a 0.1 µL/minute sample flow rate and a 
1 µL/minute sheath flow rate were used. A 1 µL/minute 
sample flow and a 10 µL/minute sheath flow were used with 
the photon multiplier tube instrument. 
In order to achieve a high signal-to-noise ratio, the maxi-
mal concentration for cell staining was established using 
routine methods in the art. Adams and Kamentsky, Acta 
Cytol. 15; 289 (1971). As shown in FIG. 4, whole blood 
samples were analyzed with different Acridine orange con-
centrations. The optimal concentration for leukocyte staining 
as determined to be approximately in the range of 1 µg/mL. In 
the particular exemplary embodiment utilized in FIG. 4, the 
distance between the coverslip and the grid surface was 
approximately 100 µm. As can be seen in FIG. 4A, an abun-
dance of erythrocytes were present under the field of view, yet 
these cells did not interfere with the fluorescent signal from 
the leukocytes, as shown in FIG. 413-F. 
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As can be seen in FIG. 5, the exemplary embodiment 
utilized in cell detection did not experience any significant 
photobleaching. The signal was fitted as a first-order expo-
nential decay with time constant of 6.4±0.7 seconds. Two 
5 more tests confirmed that the photobleaching time constant 
for one particular embodiment was between 1 second and 10 
seconds. The photobleaching time constant for one particular 
embodiment was characterized by filling the device with 
Acridine orange-stained whole blood. The channel was 
io scanned by the laser spot and the illumination was set to be the 
same as that used in testing. The entire process was recorded 
with a CCD camera. Whenever a fluorescing leukocyte was 
observed with fluorescent emission clearly distinct from the 
background, we stopped moving the laser spot and waited 
15 until the leukocyte was photobleached to background level. 
The images were extracted from the video, converted to 8-bit 
gray scale images, and analyzed with a Matlab program. The 
data was fitted to a single time-constant exponential decay. 
Additionally, green fluorescent beads were tested at a con- 
20 centration of about 2x10 3/µL, as observed by CCD camera, 
and shown in FIG. 6. Sample flow rate was set at about 3 
nL/min, and sheath flow was about 30 nL/min. In one exem-
plary test run, a hydrodynamic focused laser beam, as shown 
in FIG. 6A, created an enlarged light circle as shown in FIG. 
25 6B. Only a single bead normally appeared in each image. 
With diffused laser illumination, as shown in FIG. 6C, the 
trace of the bead could be identified, as shown in FIG. 6D. 
Hydrodynamic focusing limits the cross-sectional area of the 
detection zone without shrinking the channel diameter, thus 
30 the signal-to-noise ratio may be improved without increasing 
the risk of clogging the channel. Also, the reduction of the 
cross-section of the core flow reduces the coincidence effect. 
Finally, enclosing the core sample flow with sheath flow 
minimizes fluorescent dye absorption in the device walls, 
35 thus reducing background noise. As indicated in FIG. 7, bead 
signals from the photodiode detector could easily be identi-
fied. 
As shown in FIG. 8, using both red and green emission 
filters, images extracted from video taken by the CCD camera 
40 show the signal identified from a leukocyte stained withAcri-
dine orange, as well as the signal obtained from the fluores-
cent control bead. For photodiode detection, the expected 
leukocyte detection rate would average about 4-11 cells per 
second for a normal individual. 
45 In one exemplary embodiment, a time trace over 50 sec-
onds of an undiluted blood sample stained with Acridine 
orange using a green emission filter, and a throughput of up to 
about 1000 leukocytes per second was attained. Maxima sig-
nal intensity (peak height as in FIG. 9) from the green fluo- 
5o rescent channel with 525 nm emission filter was studied by 
plotting its histogram, as shown in FIG. 10. As expected, the 
lower-intensity portion is likely contributed mainly by lym-
phocytes, while the higher-intensity portion is likely mainly 
from monocytes, with the center-region is likely mostly from 
55 granulocytes, Steinkam et al., Acta Cytol, 17; 113-117 
(1973). 
In one exemplary embodiment, a time trace over 50 sec- 
onds of an undiluted blood sample stained with Acridine 
orange using a red fluorescent channel with 650 nm emission 
60 filter was conducted. As shown in FIG. 11, two peaks were 
identified, the lower intensity is dominated by lymphocytes 
and the higher-intensity peak is largely monocytes and granu- 
locytes. The time between the start of staining the cells to 
photodiode recording was typically greater than 15 minutes. 
65 In both exemplary studies, the maximal throughput was 
about 1000 leukocytes per second utilizing one embodiment 
of the PMT detector. By using undiluted blood, minimal 
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sample volume was maintained, which increases the through- 	 this specification and/or listed in the Application Data Sheet, 
put. Since sample throughput is proportional to volume flow 	 are incorporated herein by reference, in their entirety. 
rate, but is limited by the maximal pumping rate and response 	 The invention claimed is: 
time of the sensing system a 3 nL/minute core flow rate was 	 1. A method for analyzing leukocytes in a whole blood 
used with the CCD camera detection. Under this flow rate, a 5 sample, the method comprising: 
typical leukocyte traveled through the detection zone in 	 a) introducing a modified blood sample comprising fluo- 
approximately 30 milliseconds, which roughly equals the 	 rescently labelled leukocytes and fluorescently labeled 
CCD frame acquisition time. 	 control beads, to an inlet of a first microfluidic channel 
How rates for varying embodiments may be suitable for a 	 that gradually narrows and is directly coupled to a sec- 
range from approximately I nL/minute, approximately 2 10 	 and microfluidic channel that has fixed dimensions, 
nL/minute, approximately 3 nL/minute, approximately 4 	 wherein the fluorescently labeled leukocytes are 
nL/minute, approximately 5 nL/minute, approximately 6 
	 labelled with a fluorophore different than a fluorophore 
nL/minute, approximately 7 nL/minute, approximately 8 
	 label of the control beads, and wherein the second chan- 
nL/minute, approximately 9 nL/minute, approximately 10 	 nel having the fixed dimensions of approximately 40 
nL/minute, approximately 20 nL/minute, approximately 30 15 	 microns by approximately 50 microns, and wherein the 
nL/minute, approximately 40 nL/minute, approximately 50 
	 first channel and the second channel are obstacle-free; 
nL/minute, approximately 60 nL/minute, approximately 70 
	 b) flowing the modified blood sample from the inlet of the 
nL/minute, approximately 80 nL/minute, approximately 90 
	 first microfluidic channel, to the outlet of the second 
nL/minute, approximately 100 nL/minute, approximately 	 microfluidic channel, whereby decreasing the cross-sec- 
110 nL/minute, approximately 120 nL/minute, approxi-  20 	 tional area increases a core flow rate of the modified 
mately 130 nL/minute, approximately 140 nL/minute, 	 blood sample, such that the core flow rate is from 
approximately 150 nL/minute, or any value therebetween for 	 approximately 5 microliters/minute at a detection zone 
photodiode detection. Likewise, for PMT detection, flow 	 located in the second microfluidic channel; 
rates for varying embodiments may be suitable for a range 	 c) detecting a level of fluorescence of the fluorescently 
from approximately 200 nL/minute, approximately 300 25 	 labelled leukocytes and a level of fluorescence of the 
nL/minute, approximately 400 nL/minute, approximately 	 fluorescently labelled control beads, as they pass 
500 nL/minute, approximately 800 nL/minute, approxi- 	 through the detection zone in the second microfluidic 
mately 700 nL/minute, approximately 800 nL/minute, 	 channel, by exciting the fluorophores of the fluores- 
approximately 900 nL/minute, approximately I µL/minute, 	 cently labelled leukocytes and of the fluorescently 
approximately 2 µL/minute, approximately 3 µL/minute, 30 	 labeled control beads, wherein the detection of the leu- 
approximately 4 µL/minute, approximately 5 µL/minute, or 	 kocytes is performed on individual leukocytes; and 
any value therebetween. 	 d) using the level of fluorescence to thereby provide a result 
In one exemplary embodiment, the time response of the 	 concerning the blood sample. 
photodiode receiver module under low sensitivity setting was 	 2. The method of claim 1, wherein the method further 
0.16 milliseconds, and 0.6 milliseconds under high sensitiv-  35 comprises identifying the fluorescently labelled leukocytes. 
ity, while the time response of the PMT detector in one 	 3. The method of claim 1, wherein the method further 
exemplary run was about 16 microseconds. 	 comprises sorting the fluorescently labelled leukocytes. 
Furthermore, by decreasing the cross-sectional area, the 	 4. The method of claim 1, wherein the method further 
linear flow velocity of the core flow is increased, which 	 comprises counting the fluorescently labelled leukocytes. 
requires faster sensing, and reduces the coincidence effect by 40 	 5. The method of claim 1, further comprising recording 
increasing the average distance between cells in the detection 	 measurement on a recording unit. 
zone. 
	 6. The method of claim 1, further comprising recording the 
Thus, by utilizing particular embodiments disclosed herein 	 result on a recording unit. 
relating to a microfluidic device, leukocyte sensing, counting, 	 7. The method of claim 1, wherein the method can detect 
and sorting can be achieved one-by-one in a micro flow 45 leukocytes at arate of up to about 1000 leukocytes per second. 
cytometer system. Furthermore, dense cell suspensions, such 
	 8. The method of claim 1, further comprising using an 
as whole, undiluted blood may be utilized in certain embodi- 	 excitation source to excite the fluorophores of the fluores- 
ments described herein, which provides for reduced sample 	 cently labelled leukocytes and of the fluorescently labeled 
and waste volume, reduced processing time, and completely 	 control beads. 
eliminates on-chip mixing and buffer storage. In particular 50 	 9. The method of claim 8, wherein the excitation source is 
aspects, leukocytes can be sensed one-by-one in a micro flow 	 a laser or a LED. 
cytometer system. 	 10. The method of claim 1, wherein the excitation source 
As described herein, certain embodiments of the device 	 further comprises a lens assembly. 
can be implemented in various sizes and conformations, 	 11. The method of claim 1, further comprising measuring 
including but not limited to a bench-top device, a handheld 55 the fluorescence of the fluorescently labeled leukocytes and 
device (such as is shown in FIG. 12), an implantable device, 	 of the fluorescently labeled beads using a light sensor. 
a nanotechnology device, or other size or conformation. In the 	 12. The method of claim 11, wherein the light sensor com- 
smaller exemplary conformations, high-illumination LED is 	 prises a photomultiplier. 
used for excitation and a minipump is used to manipulate the 	 13. The method of claim 1, further comprising manipulat- 
sample in suction mode, while fluorescent signals from green 60 ing the fluorescence measurement using a computer software 
and red channels can be detected simultaneously. 	 inscribed on a computing device. 
14. The method of claim 13, further comprising displaying 
INCORPORATION BY REFERENCE 	 a result of the manipulation on a display unit. 
15. The method of claim 1, wherein the fluorescently 
All of the above U.S. patents, U.S. patent application pub-  65 labeled beads are polymeric beads. 
lications, U.S. patent applications, foreign patents, foreign 	 16. The method of claim 1, wherein the fluorescently 
patent applications and non-patent publications referred to in 	 labeled beads are polystyrene beads. 
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17. The method of claim 1, wherein the measurement of the 
fluorescence comprises using an image capture device. 
18. The method of claim 1, wherein the flow of the modi-
fied blood sample is performed by pumping the fluid sample 
	
through the microfluidic device. 	 s 
19. The method of claim 1, wherein the modified blood 
does not comprise a sheath fluid. 
